Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.

Suppr

超能文献

作者信息

Ferrari Laura, Sada Simona

机构信息

, Milan, Italy,

出版信息

Intern Emerg Med. 2015 Apr;10(3):369-71. doi: 10.1007/s11739-014-1173-5. Epub 2014 Dec 24.

DOI:10.1007/s11739-014-1173-5

PMID:25537439

Abstract

摘要

相似文献

Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.

Intern Emerg Med. 2015 Apr;10(3):369-71. doi: 10.1007/s11739-014-1173-5. Epub 2014 Dec 24.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。

N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.血管紧张素受体脑啡肽酶抑制剂与依那普利比较，对心力衰竭存活患者临床进展风险的影响。

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.血管紧张素受体-脑啡肽酶抑制剂与标准治疗相比用于射血分数降低的心力衰竭患者的估计 5 年治疗需要人数，以预防心血管死亡或心力衰竭住院：来自 PARADIGM-HF 试验的数据分析。

JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957.

PARADIGM-HF--the experts' discussion.PARADIGM-HF——专家讨论

N Engl J Med. 2014 Sep 11;371(11):e15. doi: 10.1056/NEJMp1410203. Epub 2014 Sep 3.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.射血分数对沙库巴曲缬沙坦（LCZ696）治疗射血分数降低的心力衰竭的疗效及预后的影响：ARNI与ACEI对心力衰竭全球死亡率和发病率影响的前瞻性比较（PARADIGM-HF）试验

Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.

Angiotensin receptor neprilysin inhibitors in older patients with heart failure.血管紧张素受体脑啡肽酶抑制剂用于老年心力衰竭患者

BMJ Evid Based Med. 2019 Feb;24(1):5-7. doi: 10.1136/bmjebm-2018-110949. Epub 2018 Jul 10.

In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.住院期间启动血管紧张素受体脑啡肽酶抑制剂——时机已到。

JAMA Cardiol. 2019 Mar 1;4(3):195-196. doi: 10.1001/jamacardio.2019.0104.

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.奈普利肽抑制治疗心力衰竭：一个关于科学、机缘巧合和第二次机会的故事。

Eur J Heart Fail. 2015 Mar;17(3):242-7. doi: 10.1002/ejhf.250.

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。

N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.

引用本文的文献

Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives.心力衰竭治疗的现代方法：最新进展与未来展望

Pharmaceutics. 2022 Sep 17;14(9):1964. doi: 10.3390/pharmaceutics14091964.

Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.癌症治疗相关心功能障碍患者应将血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂转换为沙库巴曲缬沙坦。

J Int Med Res. 2022 Jan;50(1):3000605211067909. doi: 10.1177/03000605211067909.

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.沙库巴曲缬沙坦在心力衰竭中的肾脏保护作用：来自真实临床环境的见解

Intern Emerg Med. 2019 Nov;14(8):1205-1208. doi: 10.1007/s11739-019-02149-6. Epub 2019 Jul 15.

[Cardio-renal axis : Relationship of heart failure and renal insufficiency as comorbidities].[心肾轴：心力衰竭与肾功能不全作为合并症的关系]

Internist (Berl). 2018 May;59(5):420-427. doi: 10.1007/s00108-018-0410-9.

Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.慢性炎症性疾病中心血管合并症的发病机制和治疗中的未满足需求。

Clin Rev Allergy Immunol. 2018 Dec;55(3):254-270. doi: 10.1007/s12016-017-8624-5.

本文引用的文献

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.血管紧张素受体脑啡肽酶抑制剂 LCZ696 治疗射血分数保留的心力衰竭的 II 期双盲随机对照试验。

Lancet. 2012 Oct 20;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6. Epub 2012 Aug 26.

Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase.肾髓质间质细胞中血管紧张素II与心房利钠肽之间的相互作用：中性内肽酶的作用

Nephron Physiol. 2006;103(3):p149-56. doi: 10.1159/000092457. Epub 2006 Mar 25.

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).奥美沙坦酯与依那普利治疗慢性心力衰竭患者的比较：奥美沙坦酯与依那普利降低事件发生率随机效用试验（OVERTURE）。

Circulation. 2002 Aug 20;106(8):920-6. doi: 10.1161/01.cir.0000029801.86489.50.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.血管紧张素受体阻滞剂缬沙坦用于慢性心力衰竭的一项随机试验。

N Engl J Med. 2001 Dec 6;345(23):1667-75. doi: 10.1056/NEJMoa010713.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.依那普利对左心室射血分数降低的充血性心力衰竭患者生存率的影响。

N Engl J Med. 1991 Aug 1;325(5):293-302. doi: 10.1056/NEJM199108013250501.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验